Burning Rock to Participate in Morgan Stanley 2020 Healthcare Conference

Rhea-AI Summary

Burning Rock Biotech Limited (NASDAQ: BNR) will participate in the Morgan Stanley Virtual Healthcare Conference on September 17 at 8:00 a.m. Eastern Time. The company's management will engage in a fireside chat, allowing for inquiries through Morgan Stanley sales representatives. Burning Rock specializes in precision oncology using next-generation sequencing (NGS) technology, holding a leading market share in China for NGS-based therapy selection testing with over 185,000 tests conducted. The firm is also advancing NGS-based cancer early detection into clinical validation.

SHANGHAI, China, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.

Burning Rock’s management is scheduled for a fireside chat on Thursday, September 17 at 8:00 a.m. Eastern Time (8:00 pm Hong Kong time). Interested parties may request more information by contacting their Morgan Stanley sales representatives.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: www.brbiotech.com.

FAQ

When will Burning Rock Biotech participate in the Morgan Stanley Virtual Healthcare Conference?

Burning Rock Biotech will participate in the Morgan Stanley Virtual Healthcare Conference on September 17 at 8:00 a.m. Eastern Time.

What is the focus of Burning Rock Biotech's technology?

Burning Rock Biotech focuses on next-generation sequencing (NGS) technology in precision oncology.

How many NGS tests has Burning Rock completed?

Burning Rock has completed over 185,000 tissue and liquid-based NGS tests cumulatively.

What stage is Burning Rock's NGS-based cancer early detection technology in?

Burning Rock's NGS-based cancer early detection technology has advanced to the clinical validation stage.

How can interested parties get more information about Burning Rock's participation in the conference?

Interested parties can request more information by contacting their Morgan Stanley sales representatives.